Form 4: Adaptive Biotechnologies CCO Acquires Shares

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, acquired 121,875 shares of common stock through two transactions.

Summary

• Susan Bobulsky, Chief Commercial Officer, MRD, of Adaptive Biotechnologies Corp (ADPT), acquired common stock.
• On March 4, 2026, she acquired 59,375 shares of common stock at a price of $0.
• On the same date, she acquired an additional 62,500 shares of common stock at a price of $0.
• Following these transactions, her direct beneficial ownership of common stock increased to 469,113 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive, as a key executive increasing their stake, likely through a compensation grant, aligns management's interests with shareholders and signals continued commitment to the company.

Positives

• Chief Commercial Officer Susan Bobulsky increased her direct beneficial ownership of Adaptive Biotechnologies common stock by a total of 121,875 shares.
• The acquisition of shares by an insider, particularly at a $0 price (likely a grant or vesting), indicates continued alignment of management's interests with shareholders.

Industry Context

StockSavvy.ai notes that insider acquisitions, especially those at a $0 price, typically represent compensation grants or vesting of restricted stock units, which are common practices in executive compensation and aim to align management's long-term interests with shareholder value.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive signal of management's confidence in the company's future prospects and alignment of interests.

Key Dates

Recommendation

The acquisition of shares by a Chief Commercial Officer, likely through a compensation grant at a $0 price, demonstrates continued alignment of management's interests with the company's performance. While this is a positive signal of insider confidence, it does not represent a direct market purchase and, without further financial or strategic disclosures, is not a standalone catalyst for a strong buy or sell recommendation.

Keywords

Adaptive Biotechnologies, ADPT, insider trading, Form 4, stock acquisition, Susan Bobulsky, Chief Commercial Officer, common stock